FLOWOOD, Miss., Oct. 16, 2013 /PRNewswire/ -- Cyres Scientific today reported favorable results from its pre-clinical in-vitro study, whose purpose was to determine the ability of its proprietary enhanced combined magnetic field bone growth stimulation technology to produce pre-osteoblast cellular proliferation. The data provided significant evidence that the Cyres Scientific technology is well suited for use as an adjunct to spinal fusion surgery, as well as to treat fresh fractures and established non-unions.
"Cyres Scientific is eager to offer patients an effective, proprietary bone growth stimulation technology. We see great potential in our therapy, and are confident that this new technology will perform well in the upcoming clinical trial," said Joel McCown, Chief Technology Officer of Cyres Scientific.
The company is currently raising capital in preparation for the clinical trial effort, with patient enrollment anticipated to begin in Q1 2015. Those interested in pursuing investment opportunities should contact Cyres Scientific through their website at www.cyressci.com.
About Cyres Scientific
Cyres Scientific is a Flowood, MS based medical device company that is focused on developing bone growth stimulator technologies for both spinal fusion and long bone applications. The company was founded in 2013 by experienced spinal fixation executives and engineers, with the purpose of improving the quality of life for patients who have undergone cervical or lumbar fusion surgery, or those who have experienced long-bone fractures or established non-unions. Prior to its inception, the company founders have been actively developing bone growth stimulator technologies, securing intellectual property, and building strategic business relationships. Cyres Scientific currently has several patents pending related to their bone growth stimulation technology.
SOURCE Cyres Scientific